3 Reasons MannKind Corporation's Stock Could Fall
MannKind is dependent on the launch of inhaled insulin Afrezza and its marketing partner Sanofi.
Why MannKind Corporation Stock Skyrocketed 38% in 2014
MannKind's stock has handily outperformed the S&P 500 in 2014. Find out what's sent its shares higher and whether or not it has more room to run.